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Abstract  
The pathogenesis, diagnosis and therapy of sarcoidosis as an autonomous disease are subjects of spirited 
discussions, which haven’t found definitive conclusion yet. Distinguishing between sarcoidosis and sarcoid-like 
reactions (sarcoid - type granulomas) is not currently a medical “gold standard” and is not implemented in clinical 
practice. This leads to 1) misinterpretation of numerous available data; 2) difficulty in the interpretation of other 
unverified data, which is often followed by 3) inappropriate or inadequate therapeutic approach. Similarly to many 
other diseases, in sarcoidosis and sarcoid - types of reactions the concept of personalised approach and therapy 
should also be introduced. This methodology of clinical guidance is difficult, complex and not always achievable in 
the current medical status and relations (doctor-patient relationship; financial factor; time factor). It is appropriate 
to note that in some cases the guidelines or the so-called standards are neglected or not possible to put into 
practice with the aim of better therapeutic practices and strategies, as well as the achievement of optimal final 
clinical results (especially in patients with sarcoid granulomas). The sarcoid granuloma, even when it is sterile, 
should not be considered as the equivalent of sarcoidosis, i.e., sarcoidosis as an autonomous disease. Sure 
enough, exactly because of this fact, the personalised approach should not be an exception, but it has to 
gradually become a rule in medical practice. When clinical decisions are conformed to some of the latest modern 
concepts, officialised in the international databases, often the achieved results can be much better. 
We present a patient with a tattoo of AC Milan (1899) on his right arm, who subsequently developed localised 
sterile sarcoid granulomas in the area of the tattoo. Later the process became generalised on his whole body’s 
skin, lungs and lymph nodes. It is unclear for the moment whether this condition should be interpreted as 
sarcoidosis as an autonomous disease or, instead, as a sarcoidal type of reaction with subsequent generalisation 
due to cross-reactivity against antigens present in other tissues with similarities to the exogenous pigments. 
Following the modern concepts regarding the pathogenesis of these two conditions, we introduced, in this case, 
an innovative, non-standard approach: 1) systemic and local immunosuppressive therapy, combined with 2) 
recommеndation for immediate surgical excision of the tattoo to remove the possible trigger of molecular and 
antigen mimicry. 
 
 
 
 
 
Introduction 
 
At the current stage of knowledge the 
definition of sarcoidosis as an autonomous disease, 
as well as the differentiation between sarcoidosis and 
sarcoid - type reactions, remain unclear and a serious 
clinical and diagnostic challenge [1].  
An accurate distinction between these two 
concepts is crucial because it presumes completely 
different clinical behaviour and therapeutic strategies 
[2]. On the other hand, it is a very serious question 
whether the term sarcoidosis has to be reconsidered 
as a non-autonomous disease but rather as a reaction 
pattern [3].  
We present an interesting patient with 
histopathologically - proven sarcoid granulomas and 
discuss the possible pathogenetic relationship 
between the disturbance of tissue homeostasis and 
granuloma formation. 
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Case report section 
 
Anamnesis 
A 42 – year - old male patient presented to 
the department of dermatologic surgery due to a rash 
on his right tight. Pruritus leading to scratching and 
bleeding was reported as a subjective complaint. The 
symptoms occurred one year and a half after 
performing a tattoo with the logo of the football team 
AC Milan (1899). The patient noticed thickening of the 
skin under the blazon, exactly in the area of the red 
pigment, which had started to disappear (Fig.1 a).  
 
Figure 1: a – Thickening of the skin under the blazon, coinciding 
with the area of the red pigment, which has started to disappear 
 
The patient had histologically proven 
cutaneous sarcoidosis from 03/2014. Therapy with 
methylprednisolone 60mg/day, with gradual tapering 
of the dose, was started. In 02/2015 systemic 
sarcoidosis was additionally proved histologically after 
a biopsy of endobronchial granulations. Throughout 
several months, dermatologic and pulmonary 
consultations were performed as well as control CT 
and chest radiography. Meanwhile, the dosage of 
methylprednisolone was slowly reduced or increased 
according to disease fluctuations. According to the 
more recent data, methylprednisolone was prescribed 
in the following doses: 01-03/2017 x 15 mg/d; 04-
06/2017 x 10 mg/d; 06-09/2017 x 5 mg/d. 
In 09/2016, treatment with methotrexate at a 
dose of 20 mg weekly was prescribed for six months, 
followed by reduction of the dose to 10 mg weekly 
until 09/2017 when the treatment was suspended. By 
the regular follow-up tests, the treatment mentioned 
above was considered inefficient. 
QuantiFERON test and serological tests (anti-
HCV and HBsAg) were negative.  
 
Physical examination 
Disseminated annular lesions with the 
atrophic centre and raised edges, well demarcated 
from the surrounded skin were observed on the scalp, 
face, trunk and upper limbs (Fig.1 b, c, d). Enlarged 
inguinal lymph nodes were identified by palpation.  
 
Ancillary tests 
Laboratory tests revealed elevated ESR – 18 
mm/h (< 11 mm/h); WBC - 31.0/l (3.5 - 10.5/l); Crystal 
- 9.0/l (-); Plasma uric acid - 526.0 mol/l (< 410 mol/l). 
Microbiological analysis of a skin swab identified S. 
aureus, sensitive to amoxicillin, cefuroxime, 
ciprofloxacin and clindamycin. 
 
Figure 2: Radiographic images taken in the last 15 months show 
relatively stable pulmonary findings, which persist in spite of the 
systemic treatment 
 
Chest radiography detected bilateral hilar 
enlargement with irregular borders, consistent with 
hilar lymphadenopathy (Fig. 2). An infiltrate with 
perihilar paracardial localisation could not be 
excluded. Horizontal linear opacities between the 
medium and lower lobes of the right lung were also 
reported (Fig. 3). 
 
Figure 3: a, b, c - Chest radiography detected bilateral hilar 
enlargement with irregular borders, which can be associated with 
hilar lymphadenopathy. An infiltrate with perihilar paracardial 
localisation cannot be excluded. Horizontal linear opacities between 
the medium and the lower lobes of the right lung were also 
observed 
 
Ultrasound examination revealed 
splenomegaly and enlarged bilateral inguinal lymph 
nodes as well as enlarged cervical lymph nodes on 
the right side of the neck, dorsal to the 
sternocleidomastoid muscle. Echocardiography 
detected upper-bound volume on the left ventricle, 
right ventricle dilatation and elevated pulmonary artery 
pressure in the right atrium. Biopsy from 10/2017 
revealed sarcoid granulomas. After endocrinology 
consultation, the patient was diagnosed with 
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hyperuricemia and started therapy with allopurinol.  
 
Treatment and outcome 
To eradicate the infectious process he 
underwent treatment with ciprofloxacin 100mg 2 x  2/d 
i.v. and local dressings with Jodasept® unguent, 
resulting in successful results. 
The patient was diagnosed with skin and 
systemic sarcoidosis. According to the clinical 
consultations he performed, treatment was inefficient 
and did not lead to any significant improvement of the 
pulmonary changes. Furthermore, the progression of 
the cutaneous lesions of sarcoidosis was observed. 
Therefore, a therapy with methylprednisolone 60 mg/d 
i.v. and azathioprine 2 x 50 mg/d for three days was 
prescribed. The ambulatory treatment proceeded with 
methylprednisolone 40 mg/d with a dose reduction of 
4 mg per week; azathioprine 50 mg 2 x 1/d; 
esomeprazole 40 mg/d and local application of 
pimecrolimus 1%/15 g cream 2 x /d. Also, the patient 
was referred to a plastic and reconstructive surgery 
department for surgical excision of his tattoo to 
permanently remove the exogenous pigment.  
 
 
Discussion  
 
Once more, we focus the attention of our 
colleaguеs and the dermatologic community on the 
pathogenesis of sarcoidosis, still defined as an 
“autonomous disease”, a concept that, in our opinion, 
should be reconsidered. A sarcoid granuloma is not 
equivalent to the disease sarcoidosis because it is 
observed as a result of 1) possible paraneoplastic 
manifestation, resulting from cross-reaction between 
antigens of the self and cancer antigens; 2) reaction 
pattern (cross-mediated or direct immunity) against 
several microbiological agents [1]. Is sarcoidosis such 
a wide-spectrum disease?  
One of the difficulties in distinguishing 
sarcoidosis as an autonomous disease from 
sarcoidal-type reactions comes from their main 
common feature, which is the presence of epithelioid 
cell granulomas [3]. However, there is no “gold 
standard” for systematic diagnostic approach and 
prediction of clinical behaviour in cases of 
histologically proven epithelioid cell granulomas [4]. 
The definition of sarcoidosis states that it is a disease 
characterised by the presence of non - caseating 
epithelioid cell granulomas in several organs and 
tissues [5]. By definition, granulomas in sarcoidosis 
are sterile, so the presence of any identifiable 
immunogenic triggering agents makes it more 
accurate to refer to this reaction as a sarcoidal type of 
reaction pattern [6][7]. In our opinion, sterile sarcoid 
granuloma should not equate to sarcoidosis disease. 
The triggering mechanisms that induce sarcoid-like 
reactions may be categorized as following: 1) local 
reaction to infectious agents (leprosy, atypical 
mycobacterial infections, deep fungal reactions, etc.) 
[8][9][10]; 2) noninfectious but immunogenic antigens 
(inorganic compounds) [11][12]; 3) tumors 
(paraneoplastic sarcoid type of reaction) [13][14]. Our 
concepts of sarcoid - type reaction are based on the 
assumption that it may be provoked, in predisposed 
patients, by cross-reaction to immunogens or tumour 
antigens, so its pathogenesis is closely related to the 
generation of cross - mediated immunity presenting as 
molecular (antigen) mimicry. This phenomenon occurs 
by the similarity between certain amino acid 
sequences in the triggering antigens and molecular 
structures in the body [15]. The precise distinction 
between these two terms is extremely important 
because misdiagnosis may lead to the introduction of 
inappropriate treatment.  Immunosuppressive therapy, 
which is recommended as first-line treatment for 
sarcoidosis, can enhance a tumour or infectious 
progression in patients afflicted by those conditions, 
with all its deleterious consequences for the patient 
[16][17][18]. 
Blau syndrome (BS), for example, is a rare 
autosomal dominant autoinflammatory disease 
characterised by the clinical triad of dermatitis, 
arthritis, and uveitis. It is caused by mutations in 
nucleotide-binding oligomerisation domain-containing 
protein - 2 (NOD2) gene [19]. It is unclear whether 
and to what extent this autoinflammatory syndrome 
overlaps with congenital or early-onset sarcoidosis, 
which is most probably genetically determined [20]. It 
is a somewhat disturbing fact that the mechanism of 
granuloma formation in these patients is completely 
different from the one that originates similar types of 
granulomas in patients with certain forms of cancer or 
deep mycosis. Sarcoid granulomas are obviously the 
final result of diverse pathogenic mechanisms, which 
are, in turn, activated by different specific diseases 
[1][21].  
Would it be accurate to define existing 
sarcoidosis as a disease occurring by 1) congenital 
genetic defect; 2) paraneoplastic reaction; 3) 
parainfectious or infectious disease, as well as the 
incorporation of inorganic material via inhalation or 
skin contact?   
According to our observations, sarcoid-like 
reactions could be determined by the capability of the 
organism (or a genetically determined predisposition) 
for reacting against different kinds of antigens. These 
antigens could be either exogenously incorporated 
into the body or generated by the tissue homeostasis 
(de novo) as seen in the process of carcinogenesis. 
This abnormality of tissue homeostasis is the main 
trigger of sarcoid-like reactions [22]. Thus, clinicians 
should be cautious in the approach to this kind of 
reactions. In case of a histological diagnosis of 
sarcoid granulomas, it is of great importance to 
exclude: 1) different forms of tumours; 2) infectious 
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diseases with diverse origin. Following the standard 
definition of sarcoidosis and starting 
immunosuppressive therapy may lead to a significant 
risk of potentiating cancer progression or worsening of 
an underlying infection, which may have fatal 
consequences, as we already unravelled. 
In conclusion, we consider the present case 
of a patient with a sarcoid-like reaction secondary to a 
tattoo, as an illustrative example of our theory of 
antigen mimicry as the mechanism leading to 
granuloma formation in genetically predisposed 
individuals. The persistence of symptoms in spite of 
treatment with corticosteroids followed by 
methotrexate in combination with corticosteroids is not 
unique in the setting of sarcoidosis or sarcoid type 
reactions. In such patients, we hypothesise that it is of 
vital importance to eliminate the trigger of molecular 
mimicry, which may potentially lead to normalization 
of the tissue homeostasis and the immune response.  
It remains an open question: Sarcoidosis – does it 
exist? 
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